CORZ

Core Scientific's stock has gained approximately 19.6% to 10.75% in the past six months and over 151% in the past year, with a year-to-date increase of 53.57%. Key events include a $347.2 million net loss reported in Q1 2026 due to non-cash impairment charges, despite revenue increasing to $115.2 million. The strategic shift to AI/HPC, expansion plans in Oklahoma and Texas, and a $3.3 billion financing round have also impacted the stock. Insider trading events include an officer selling 10,000 shares and another insider purchasing 7,000 shares.